Michael Essmann
Overview
Explore the profile of Michael Essmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brincks E, Adams J, Wang L, Turner B, Marcinowicz A, Ke J, et al.
Oncotarget
. 2020 Jul;
11(25):2438-2461.
PMID: 32637034
Indoximod has shaped our understanding of the biology of IDO1 in the control of immune responses, though its mechanism of action has been poorly understood. Previous studies demonstrated that indoximod...
2.
Folkers B, Schuring C, Essmann M, Larsen B
N Am J Med Sci
. 2012 May;
2(1):5-10.
PMID: 22624106
Background: Probiotic microorganisms are potential treatments for Clostridium difficile diarrheal disease (CDD) but better methods are needed to determine the relative potency of probiotic microorganisms against pathogenic organisms in mixed...
3.
Vu B, Essmann M, Larsen B
Mycopathologia
. 2009 Oct;
169(3):183-91.
PMID: 19876762
Candida albicans at times resides in the intestinal tract, where it experiences exposure to bile salts suggesting a study of the effects of crude bile salts in the form of...
4.
De Seta F, Schmidt M, Vu B, Essmann M, Larsen B
J Antimicrob Chemother
. 2008 Dec;
63(2):325-36.
PMID: 19059942
Background: Boric acid is a commonly cited treatment for recurrent and resistant yeast vaginitis, but data about the extent and mechanism of its antifungal activity are lacking. Objectives: The aim...
5.
McCool L, Mai H, Essmann M, Larsen B
Infect Dis Obstet Gynecol
. 2008 Jun;
2008:493508.
PMID: 18528520
Object: To determine if tetracycline, previously reported to increase the probability of developing symptomatic vaginal yeast infections, has a direct effect on Candida albicans growth or induction of virulent phenotypes....
6.
Schmidt M, Barker S, Essmann M, Larsen B
Environ Toxicol Chem
. 2008 May;
27(11):2346-51.
PMID: 18476751
The ubiquitous yeast Candida albicans becomes a troublesome pathogen by inducing virulence factors in response to environmental stimuli. Among these virulence factors is a drug-exporting transport protein, Cdrlp, which renders...
7.
Hollmer C, Essmann M, Ault K, Larsen B
Infect Dis Obstet Gynecol
. 2007 May;
2006:98218.
PMID: 17485817
Background: Pathogenesis of mucosal microorganisms depends on adherence to the tissues they colonize and infect. For Candida albicans, cell surface hydrophobicity may play a significant role in tissue binding ability....
8.
Larsen B, Anderson S, Brockman A, Essmann M, Schmidt M
Yeast
. 2006 Aug;
23(11):795-802.
PMID: 16921553
The Candida albicans CDR1 gene, encoding an ABC transporter that functions as an efflux pump, is thought to be involved in pathogenic adaptation and uses mammalian hormones and other environmental...
9.
Colling L, Essmann M, Hollmer C, Larsen B
Infect Dis Obstet Gynecol
. 2005 Aug;
13(3):171-7.
PMID: 16126503
Objective: To determine whether several topical compounds and other chemical entities are able to diminish the surface hydrophobicity of yeast cells. Method: Hydrophobicity of yeast cells was determined by binding...
10.
Warolin J, Essmann M, Larsen B
Ann Clin Lab Sci
. 2005 Aug;
35(3):302-11.
PMID: 16081588
Several cytoplasmic virulence factors of Candida albicans are altered in the presence of estrogen and this fact may imply the existence of a global virulence regulatory system in this organism....